None

Zevalin Effective in Follicular NHL Refractory to Rituximab

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the r...

Consolidation with Zevalin Significantly Improves Progression-Free Survival in Advanced Follicular Lymphoma

Consolidation therapy with Zevalin® (ibritumomab tiuxetan) significantly prolongs progression-free survival and leads to high conversion rates from partial response to complete response in patients w...

Spectrum Pharmaceuticals Initiates Phase 3 Study of ZEVALIN in Patients with Newly Diagnosed ...

There is a substantial need for better treatments for DLBCL, which has low survival rates at five years; there are an estimated 20,000 new cases of DLBCL in the U.S. each year The ZEST study...

Zevalin Effective in Relapsed/Refractory Follicular Lymphoma

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) produces statistically and clinically significant higher overall response rates and complete response rates compared to Rituxan® (ri...

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients...

Spectrum Pharmaceuticals Highlights Promising ZEVALIN, FOLOTYN and Belinostat Clinical Data Presented at the 54th Annual Meeting of the American Society of Hematology

Investigator-sponsored studies report findings for ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use in diverse settings and potential new indications: First-line consolidation in pat...

Spectrum begins Phase 3 DLBCL trial of Zevalin

Spectrum Pharmaceuticals has started enrolling patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in a randomised Phase 3 Zevalin Evaluation as Sequential Therapy (ZEST) trial of Zeva...

Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients...

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma.

PURPOSE: The aim of this study was to evaluate the efficacy and side effects of radioimmunotherapies with Zevalin(®) (RIT-Z) in Japanese patients with low-grade B-cell non-Hodgkin lymphoma (NHL). MAT...

New antibody drug treatments for lymphoma.

Introduction: The advent of anti-CD20 monoclonal antibody (mAb) rituximab heralded a new era in the treatment of non-Hodgkin's lymphoma leading to significant improvements in outcome for patients. Thi...

Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after (90)Y-ibritumomab-tiuxetan.

Radioimmunotherapies with Zevalin® (RIT-Z) showed encouraging results in patients with relapsed/refractory follicular lymphoma (FL), leading frequently to failure-free intervals longer than those ach...